Introducing Arletta Pharma Solutions
In an exciting development for women's healthcare, Freya Pharma Solutions has announced its rebranding to Arletta Pharma Solutions, effective December 1, 2025. This significant transformation highlights the company’s evolution as it moves toward finalizing the clinical development of its flagship product, Lybrido™. The change not only marks a new identity but also emphasizes a deeper commitment to addressing the unique medical needs of women, particularly those suffering from Female Sexual Disorders.
The Symbolism Behind the Name
The name Arletta draws inspiration from a rare butterfly species, symbolizing transformation and change. This reflects the company's journey from its inception to the current phase where it seeks to provide innovative solutions for women's health issues. Like a butterfly emerging from a cocoon, the rebranding signifies Arletta's readiness to take flight in the healthcare landscape, facilitating essential medical advancements.
Commitment to Women’s Health
Women experience various phases throughout their lives, from puberty to menopause, each accompanied by unique health challenges. The butterfly serves as a universal symbol of these changes, representing beauty, freedom, and the intricate transitions women undergo. Arletta Pharma Solutions is dedicated to addressing these transitions through targeted therapeutic solutions aimed at improving the quality of life for women worldwide.
Advancing Clinical Programs
Arletta is currently conducting a Phase II study of the Clitoral Doppler Duplex Ultrasonography (CDU) at a prominent medical center, evaluating the effectiveness of testosterone-sildenafil dose-combination treatments in premenopausal women diagnosed with Female Sexual Interest/Arousal Disorder (FSIAD). The results are anticipated to provide vital insights into this condition, while preparations for the ALETTA pivotal study are also underway, set to take place across multiple European sites. This research is crucial for laying the groundwork for regulatory approvals.
The Innovative Lybrido™
At the heart of Arletta’s mission is Lybrido™, an on-demand dual-action therapy created for FSIAD and Hypoactive Sexual Desire Disorder (HSDD). This innovative treatment harnesses a unique dual-route, dual-release mechanism that synchronizes medication intake with sexual arousal responses, enhancing women’s sexual health. After extensive research over the past fifteen years, Lybrido™ is poised to make a significant impact on therapies available to women, building on the company’s robust scientific foundation.
The Importance of Addressing Female Sexual Disorders
Female Sexual Disorders, particularly low sexual desire, can significantly affect a woman’s emotional well-being and intimate relationships. The definition of FSIAD in the Diagnostic and Statistical Manual of Mental Disorders underscores the importance of addressing these issues, as they can lead to profound distress. Arletta Pharma Solutions recognizes the pressing need for effective treatments in this area, aiming to provide relief through their scientifically-backed therapy solutions.
About Arletta Pharma Solutions
Based in Amsterdam, Arletta Pharma Solutions strives to champion women's health through innovative medication. With a commitment to research and development, the company aims to present personalized, effective solutions for addressing FSIAD and HSDD. Their vision is clear: to meet the unmet medical needs of women worldwide.
Frequently Asked Questions
What is the significance of the name Arletta?
The name Arletta symbolizes transformation and change, reflecting the company’s journey in advancing women's healthcare and its commitment to innovation.
What are the clinical programs currently underway?
Arletta is conducting a CDU Phase II study and is preparing for the ALETTA pivotal study, evaluating therapies for Female Sexual Interest/Arousal Disorder.
What is Lybrido™?
Lybrido™ is an on-demand dual-action therapy designed for FSIAD and HSDD, featuring a unique dual-route, dual-release mechanism for enhanced efficacy.
How does Arletta Pharma Solutions support women's health?
Arletta focuses on developing targeted therapies for conditions affecting women, particularly the challenges arising from Female Sexual Disorders.
What sets Arletta apart from other pharmaceutical companies?
With over fifteen years of research, Arletta combines scientific innovation with a deep understanding of women's health to deliver effective therapeutic solutions.
